The purpose of the study is to evaluate the safety and efficacy of ceftriaxone treatment in amyotrophic lateral sclerosis (ALS). Ceftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial infections but not for treating ALS. Also, ceftriaxone has not been given to people over a long period of time, such as months or years. The goals of this study are to evaluate the safety and effectiveness of ceftriaxone as a treatment for ALS, and to determine the safety and effectiveness of long-term use of the drug in people with ALS. Created By Lingling Peng linglp0122
url: https://fair.dap.c-path.org/#/data/datasets/fv2_als1002_2025_03_25 title: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (Phase 3) sameAs: cpath:1725 source: Critical Path Institute creator: Cytokinetics, Inc. species: Homo sapiens subject: amyotrophic lateral sclerosis keywords: Amyotrophic Lateral Sclerosis, ALS, CK-2127107, Reldesemtiv, COURAGE-ALS publisher: Critical Path Institute collection: ALS Knowledge Portal
Drop files to upload
Clinical Trial Ceftriaxone in Subjects With ALS page is loading…